Status:
COMPLETED
Analgesic Effect of Ropivacaine Combined With Hydromorphone for CSEA After Total Knee Arthroplasty
Lead Sponsor:
Second Hospital of Jilin University
Conditions:
Postoperative Analgesia
Eligibility:
All Genders
55-80 years
Phase:
NA
Brief Summary
The aim of this study is to investigate the continuous analgesic effect and side effects of ropivacaine combined with hydromorphone for combined spinal-epidural anesthesia(CSEA) after total knee arthr...
Detailed Description
For patients undergoing total knee arthroplasty, different spinal anesthesia drugs were injected in the two groups. The spinal anesthetic drugs injected in the hydromorphone group were hydromorphone 5...
Eligibility Criteria
Inclusion
- Age between 55 and 80 years old.
- ASA grade I to III.
- BMI:20-29kg/m2.
- No recent use of sedatives, opioids, or other analgesics.
- There was no contraindication of spinal anesthesia, severe dysfunction of heart, lung and other important organs or serious systemic diseases.
- Patients were willing to participate in the study and signed the informed consent.
Exclusion
- The patient has mental illness or cannot cooperate with the completion of spinal anesthesia.
- The patient had a history of spinal surgery and spinal deformity.
- Patients had a history of opioid intolerance or adverse reactions.
- puncture site infection, coagulopathy or recent use of anticoagulant drugs.
- History of allergy to local anesthetics.
- Failed puncture.
- Unable to cooperate to complete the research process.
Key Trial Info
Start Date :
October 27 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2023
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT06205199
Start Date
October 27 2022
End Date
November 30 2023
Last Update
January 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Second Hospital of Jilin University
Changchun, Jilin, China